Not sure where you get the idea that time to bowl movement wouldn't be important to chronic pain users or that PGNX/Salix isn't focused on the chronic pain market. I am also not sure why you don't think a 2 year lead wouldn't be significant if two drugs were equal.
Market Data 
Markets 
AI
